VTCN1 and cancer: Aberrant B7x expression is associated with tumour necrosis, stage, grade, epithelial–mesenchymal transition (EMT), and survival outcomes such as progression free survival (PFS) and overall survival (OS), making it a potential blood biomarker in many cancers [11,12,13,14].